MONTREAL, QUEBEC--(Marketwired - Aug. 19, 2016) - Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the "Company" or "Relevium") is pleased to announce that it has completed closing of its previously announced private placement.
The Company has issued an aggregate amount of 5,058,000 units of the Company (the "Units") at a price of $0.10 per Unit, for gross proceeds of $505,800 to the Company (the "Private Placement"). Each Unit consists of one common share of the Company (a "Common Share") and one Common Share purchase warrant entitling the holder thereof to purchase one Common Share at a price of $0.15 until August 19, 2019. Each Unit will be subject to a statutory hold period of four months and one day from the date of closing.
The Company will use the proceeds from the Private Placement for general corporate purposes.
The Private Placement is subject to the final approval of the TSX Venture Exchange ("TSXV") as well as other customary closing conditions. Pursuant to an announcement made on July 6, 2016, a portion of the private placement representing 1,500,000 units is further subject to the approval by the shareholders of Maestro Capital Corporation (the subscriber) and the funds will be held in trust until such approval takes place on or before August 31, 2016.
In connection with the Private Placement, the Company paid finder fees in the amount of $2,000 in cash plus 20,000 in Broker Warrants.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities of 1933, as amended, or any state securities laws and may not be offered or sold within the United States, unless an exemption from such registration is available.
About Relevium Technologies Inc.
Relevium is a TSXV listed company focused on growth through the acquisition of businesses, products and/or technologies within the scope of the expanding health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Leena Lakdawala, CEO and Director
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the business and operations of the Company. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the ability of the Company to execute and achieve its business objectives. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. There can be no assurance that the conditions to the transactions contemplated by the potential letter of intents will be satisfied or that those transactions will be completed. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.